Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10254273 | 1.00 | HTR2C (0.33) | HTR2CSLC6A4HTR2AATMTTK | |
| SCHEMBL499317 | 1.00 | HTR2C (0.33) | HTR2CSLC6A4HTR2AATMTTK | |
| SCHEMBL499316 | 1.00 | HTR2C (0.33) | HTR2CSLC6A4HTR2AATMTTK | |
| SCHEMBL499754 | 0.91 | HTR2C (0.33) | HTR2CSLC6A4ATMPDK2HTT | |
| SCHEMBL499753 | 0.91 | HTR2C (0.33) | HTR2CSLC6A4ATMPDK2HTT | |
| SCHEMBL499755 | 0.91 | HTR2C (0.33) | HTR2CSLC6A4ATMPDK2HTT | |
| SCHEMBL10254301 | 0.91 | HTR2C (0.33) | HTR2CSLC6A4ATMPDK2HTT | |
| SCHEMBL499679 | 0.90 | ATM (0.34) | ATMTTKLMNAMAPTHTT | |
| SCHEMBL4812365 | 0.90 | ATM (0.34) | ATMTTKLMNAMAPTHTT | |
| SCHEMBL499010 | 0.85 | PDK2 (0.35) | HTR2CSLC6A4HTR2AATMTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106221-B2 | Renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | HTR2C 2973/4885SLC6A4 603/4885HTR2A 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.